Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Angiotensin-Converting Enzyme Inhibition for the Treatment of Hypertension: New Findings in Old Subjects
Medscape, 11-5-04

This study, based in Australia, followed cardiovascular outcomes in elderly patients suffering from hypertension who were randomized to receive either an angiotensin-converting enzyme inhibitor (ACE inhibitor) or a diuretic. After 4 years of treatment, similar blood pressure reductions were noted in both groups (-26/-12 mm Hg), but the ACE inhibitor achieved an “11% reduction in cardiovascular outcomes and death for subjects” relative to the diuretic group. “These findings suggesting that an [ACE inhibitor] are as effective in lowering blood pressure as diuretics in elderly hypertensives…and conferring an additional benefit beyond that from blood pressure reduction alone, are discussed in context of recent trials comparing newer vs. older antihypertensive drug treatments in elderly subjects.”

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000